Powered by

Inflazome Appoints Dr Thomas Jung as Chief Medical Officer

Nov 29, 2018 - Marketline Newswire

Inflazome, the pioneering inflammasome company, appointed Dr Thomas Jung M.D., Ph.D., as its Chief Medical Officer.

Dr Jung joins Inflazome’s senior management team to lead the clinical development of its potent and selective small-molecule inhibitors of the NLRP3 inflammasome. Dr Jung will oversee the company's global operations related to the development of Inflazome’s lead and next-generation compounds across a range of therapeutic indications; and will work collaborativ...